Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Feb;46(2):1013-1017.
doi: 10.1007/s10072-024-07886-x. Epub 2024 Nov 25.

Home-based, computer-assisted cognitive rehabilitation for attention in pediatric onset multiple sclerosis: a randomized, multicenter pilot study

Camilla Masciulli  1 , E Portaccio  2 , B Goretti  2 , C Niccolai  3 , M Simone  4 , R G Viterbo  5 , M Zaffaroni  6 , L Pippolo  6 , E Cocco  7 , G Fenu  7 , E Carta  7 , M Falautano  8   9 , C Celico  8   9 , M Pardini  10   11 , G L Mancardi  10 , R Guerrini  12 , F Melani  12 , F Giovannelli  2 , M Rocca  8   9 , P Iaffaldano  13 , A Tacchino  14 , P Zaratin  15 , M Filippi  8   9 , M P Amato  2   3
Affiliations
Randomized Controlled Trial

Home-based, computer-assisted cognitive rehabilitation for attention in pediatric onset multiple sclerosis: a randomized, multicenter pilot study

Camilla Masciulli et al. Neurol Sci. 2025 Feb.

Abstract

Objective: Cognitive impairment affects approximately 30% of pediatric onset Multiple Sclerosis (POMS) patients with a negative impact on everyday life. The aim of this study was to evaluate the feasibility and effectiveness of a home-based, computer-assisted training of attention in patients with POMS.

Methods: This was a randomized double-blind study. Subjects were randomized to specific training (ST) or non-specific training (n-ST), delivered through a customized module based on attention exercises (COGNI-TRAcK2). The main feature of the ST is the implementation of working load algorithms and procedures for intensiveness regulation. The effectiveness of the ST on attention was primarily assessed on the Symbol Digit Modalities Test (SDMT), using the Wilcoxon signed-rank test. Secondary objectives included effectiveness on other cognitive tests. The evaluations were performed at baseline, end of training and 3-month follow-up.

Results: 22 relapsing-remitting patients were included: data of 8 subjects in n-ST and 5 subjects in ST were available. As for the primary outcome, SDMT score improved in the ST group (from 31.2 at baseline to 42.4 after 3 months, p = 0.043). There was no benefit in other neuropsychological measures.

Conclusions: These preliminary findings point to a potential benefit of a home-based, computer-assisted training of attention in patients with POMS.

Keywords: Adolescent; Child; Cognitive dysfunction; Cognitive training; Multiple sclerosis; Neuropsychological tests.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: All subjects gave their informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the Ethics Committee. The protocol of the study was written in accordance to “Norma UNI EN ISO 14155 and Good Clinical Practice”. The promoter is committed to the protection of personal sensitive data in accordance with national (D.Lgs. 196/2003) and international law (European Regulation 679/2019). Conflict of interest: E.P. received compensation for travel grants, participation in advisory board and/or speaking activities from Biogen, Merck Serono, Sanofi, Teva, and Novartis and serves on the editorial board of Frontiers in Neurology and Brain Sciences. RG received fees for Advisory Boards from UCB, Zogenix, Biocodex, GW-Jazz, Angelini, Takeda, and Rapport Therapeutics, and was an investigator in the STICLO-Italy trial of stiripentol. F.M. is employees of GeneDx. M.A.R. received consulting fees from Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche; and speaker honoraria from AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. She receives research support from the MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. She is Associate Editor for Multiple Sclerosis and Related Disorders. P.I. has served on scientific advisory boards for Biogen Idec, Bayer, Teva, Roche, Merck Serono, Novartis, and Genzyme and has received funding for travel and/or speaker honoraria from Sanofi Aventis, Genzyme, Biogen Idec, Teva, Merck Serono, and Novartis. M.F. is Editor-in-Chief of the Journal of Neurology, Associate Editor of Human Brain Mapping, Neurological Sciences, and Radiology; received compensation for consulting services from Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi; speaking activities from Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA; participation in Advisory Boards for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda; scientific direction of educational events for Biogen, Merck, Roche, Celgene, Bristol-Myers Squibb, Lilly, Novartis, Sanofi-Genzyme; he receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. M.P.A. served on scientific advisory boards for and has received speaker honoraria and research support from Biogen Idec, Merck Serono, Bayer Schering Pharma, and Sanofi Aventis and serves on the editorial board of Multiple Sclerosis Journal and BMC Neurology.

References

    1. Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RHB, Zipp F, Weinstock-Guttman B (2024) Multiple sclerosis. Lancet 403(10422):183–202. https://doi.org/10.1016/S0140-6736(23)01473-3 - DOI - PubMed
    1. Ruano L, Branco M, Portaccio E, Goretti B, Niccolai C, Patti F, Chisari C, Gallo P, Grossi P, Ghezzi A, Roscio M, Mattioli F, Stampatori C, Simone M, Viterbo RG, Amato MP (2018) Patients with paediatric-onset multiple sclerosis are at higher risk of cognitive impairment in adulthood: an Italian collaborative study. Mult Scler 24(9):1234–1242 - DOI - PubMed
    1. Tarantino S, Proietti Checchi M, Papetti L, Monte G, Ferilli MAN, Valeriani M (2024) Neuropsychological performances, quality of life, and psychological issues in pediatric onset multiple sclerosis: a narrative review. Neurol Sci 45(5):1913–1930. https://doi.org/10.1007/s10072-023-07281-y - DOI - PubMed
    1. Hubacher M, DeLuca J, Weber P, Steinlin M, Kappos L, Opwis K, Penner IK (2015) Cognitive rehabilitation of working memory in juvenile multiple sclerosis-effects on cognitive functioning, functional MRI and network related connectivity. Restor Neurol Neurosci 33(5):713–25. https://doi.org/10.3233/RNN-150497 - DOI - PubMed
    1. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173. https://doi.org/10.1016/S1474-4422(17)30470-2 - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources